We are interested in all innovative “best-in-class” products, from the target stage to late-stage clinical trials, provided they bring true therapeutic innovation to areas of unmet needs.
We are also interested in licensing marketed, or near-market, products that complement our existing portfolio.
Out-licensing: We are looking for partners in the United States and Japan to license some of our drug candidates and medicinal products, and global partners for non-strategic products.
What types of agreements?
- Global rights with or without the United States and Japan
- Local and regional agreements
- R&D collaborations starting immediately or after option exercise